How can genetic advances impact on experimental models of encapsulating peritoneal sclerosis?

Peritoneal Dialysis International

Volumn 28, Issue SUPPL. 5, 2008, Pages

  Summers, Angela M ^a   Hoff, Catherine M ^b   Topley, Nicholas ^c  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Experimental; Genetics; Peritoneal sclerosis

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTISENSE OLIGODEOXYNUCLEOTIDE; CATALASE; CHLORHEXIDINE GLUCONATE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DIALYSIS FLUID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; HAMMERHEAD RIBOZYME; HEAT SHOCK PROTEIN 47; INTERLEUKIN 6; PIRFENIDONE; SCATTER FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

CELL REGENERATION; DISEASE COURSE; DRUG MECHANISM; ENCAPSULATING PERITONEAL SCLEROSIS; GENE THERAPY; HEREDITY; HUMAN; MESOTHELIUM CELL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; ANIMAL EXPERIMENT; DRUG EFFECT; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; PERITONEUM; SCLEROSIS;

ANIMAL EXPERIMENTATION; ANIMALS; DIALYSIS SOLUTIONS; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PERITONEAL DIALYSIS; PERITONEUM; SCLEROSIS;

EID: 67149107429     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080802805s04     Document Type: Review

References (46)

1. Weber J, Mettang T, Mayer-Wehrstein R, Kuhlmann U. [Continuous ambulatory peritoneal dialysis. Patient and method survival rate, peritonitis incidence and dialysis efficacy over 10 years]. Dtsch Med Wochenschr 1991; 116: 641-8.
2. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998; 13:154-9.
3. de Freitas D, Jordaan A, Williams R, Alderdice J, Curwell J, Hurst H, et al. Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis. Perit Dial Int 2008; 28:271-6.
4. Junor BJ, McMillan MA. Immunosuppression in sclerosing peritonitis. Adv Perit Dial 1993; 9:187-9.
5. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20(Suppl 4):S43-55.
6. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(Suppl 4):S39-47.
7. Kawanishi H. Surgical treatment for encapsulating peritoneal sclerosis. Adv Perit Dial 2002; 18:139-43.
8. de Freitas DG, Hurst H, Jordaan A, Tavakoli A, Brenchley PEC, Hutchison AJ, et al. Encapsulating peritoneal sclerosis (EPS) following renal transplantation [Abstract]. Perit Dial Int 2006; 26(Suppl 2):S116.
9. Fieren MW, Betjes MG, Korte MR, Boer WH. Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int 2007; 27:619-24.
10. Oules R, Challah S, Brunner FP. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 1988; 3:66-9.
11. Lo WK, Chan KT, Leung AC, Pang SW, Tse CY. Sclerosing peritonitis complicating continuous ambulatory peritoneal dialysis with the use of chlorhexidine in alcohol. Adv Perit Dial 1990; 6:79-84.
12. Fracasso A, Coli U, Landini S, Morachiello P, Righetto F, Scanferla F, et al. Peritoneal sclerosis. Role of plasticizers. ASAIO Trans 1987; 33:676-82.
13. Nakamoto H, Imai H, Ishida Y, Yamanouchi Y, Inoue T, Okada H, et al. New animal models for encapsulating peritoneal sclerosis - role of acidic solution. Perit Dial Int 2001; 21(Suppl 3):S349-53.
14. Ishii Y, Sawada T, Shimizu A, Tojimbara T, Nakajima I, Fuchinoue S, et al. An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant 2001; 16:1262-6.
15. Levine S, Saltzman A. Abdominal cocoon: an animal model for a complication of peritoneal dialysis. Perit Dial Int 1996; 16:613-16.
16. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004; 65:1927-36.
17. Abe K, Miyazaki M, Yoshio Y, Nishino T, Furusu A, Harada T, et al. Angiotensin II blockade ameliorates peritoneal fibrosis and angiogenesis in mouse experimental model of peritoneal fibrosis caused by chlorhexidine gluconate [Abstract]. J Am Soc Nephrol 2002; 13:309A.
18. Suga H, Teraoka S, Ota K, Komemushi S, Furutani S, Yamauchi S, et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol 1995; 47:287-91.
19. Hirahara I, Ogawa Y, Kusano E, Asano Y. Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats. Nephrol Dial Transplant 2004; 19:1732-41.
20. Ro Y, Hamada C, Inaba M, Io H, Kaneko K, Tomino Y. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant 2007; 22:2838-48.
21. Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, Harada T, et al. Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int 2003; 64:887-96.
22. Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, Mizuta Y, et al. TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int 2004; 66:1677-85.
23. Fukuoka N, Sugiyama H, Inoue T, Kikumoto Y, Takiue K, Morinaga H, et al. Increased susceptibility to oxidant-mediated tissue injury and peritoneal fibrosis in acatalasemic mice. Am J Nephrol 2008; 28:661-8.
24. Hoff CM. Experimental animal models of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(Suppl 4): S57-66.
25. Williams JD, Craig KJ, Topley N, von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
26. Breborowicz A, Karon J, Korybalska K, Martis L, Oreopoulos DG. Functional properties of mesothelial cells after prolonged exposure to dialysate effluent. Adv Perit Dial 1995; 11:15-18.
27. Higuchi C, Tanihata Y, Nishimura H, Naito T, Sanaka T. Effects of glucose and plasminogen activator inhibitor-1 on collagen metabolism in the peritoneum. Ther Apher Dial 2005; 9:173-81.
28. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001; 12:2029-39.
29. Margetts PJ, Kolb M, Yu L, Hoff CM, Gauldie J. A chronic inflammatory infusion model of peritoneal dialysis in rats. Perit Dial Int 2001; 21(Suppl 3):S368-72.
30. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003; 23: 530-41.
31. Hirahara I, Kusano E, Yanagiba S, Miyata Y, Ando Y, Muto S, et al. Peritoneal injury by methylglyoxal in peritoneal dialysis. Perit Dial Int 2006; 26:380-92.
32. Topley N. Animal models in peritoneal dialysis: more questions than answers? Perit Dial Int 2005; 25:33-4.
33. Imai H, Nakamoto H, Fucshima R, Yamanouchi Y, Ishida Y, Suzuki H. Glucocorticoid protects against the development of encapsulating peritoneal sclerosis on peritoneal dialysis. Adv Perit Dial 2002; 18:124-30.
34. Hoff CM, Margetts PJ. Adenovirus-based transient expression systems for peritoneal membrane research. Perit Dial Int 2006; 26:547-58.
35. Hoff CM, Piscopo D, Svatek JM, Holmes CJ, Honda K, Margetts PJ. Pilot study to establish an experimental animal model of EPS: potential contributing factors [Abstract]. Perit Dial Int 2004; 24(Suppl 2):S4.
36. Matsuoka T, Maeda Y, Matsuo K, Naiki Y, Tamai Y, Sakaguchi M, et al. Hepatocyte growth factor prevents peritoneal fibrosis in an animal model of encapsulating peritoneal sclerosis. J Nephrol 2008; 21:64-73.
37. Maruyama N, Fukuda N, Okada K, Matsumoto K. [Development of gene therapy for encapsulating peritoneal sclerosis by a chimeric DNA-RNA hammerhead ribozyme targeting TGF-beta1 mRNA]. Nippon Jinzo Gakkai Shi 2007; 49:113-20.
38. Aroeira LS, Aguilera A, Sanchez-Tomero JA, Bajo MA, del Peso G, Jimenez-Heffernan JA, et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 2007; 18:2004-13.
39. De Vriese AS, Tilton RG, Mortier S, Lameire NH. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 2006; 21:2549-55.
40. Nishioka Y, Miyazaki M, Abe K, Furusu A, Harada T, Ozono Y, et al. Regeneration of peritoneal mesothelium in a rat model of peritoneal fibrosis. Ren Fail 2008; 30:97-105.
41. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999; 60:1245-9.
42. Cambien F, Ricard S, Troesch A, Mallet C, Generenaz L, Evans A, et al. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 1996; 28:881-7.
43. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000; 37:443-8.
44. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000; 12:1232-5.
45. Gillerot G, Goffin E, Michel C, Evenepoel P, Van Biesen W, Tintillier M, et al. Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int 2005; 67:2477-87.
46. Summers AM, Brenchley PEC. An international encapsulating peritoneal sclerosis registry and DNA bank. Why we need one now. Perit Dial Int 2006; 26:559-63.